Invivyd appointed Marc Elia, its Chairman of the Board, as Chief Executive Officer effective August 30, 2026. Elia receives a $750,000 annual base salary, a target bonus of 70% of base, and a one-time sign-on bonus of $500,000. He was granted an option to purchase 10,700,000 shares vesting over four years. The Board also increased its size to seven directors and appointed Ian Sheffield as an independent director. Concurrently, Ajay Royan was named Lead Independent Director. The company expects top-line data from the VYD2311 clinical studies around the end of Q3 2026, with plans to submit a Biologics License Application for its anti-COVID-19 monoclonal antibody candidate. Invivyd is a biopharmaceutical company developing monoclonal antibodies for viral infectious diseases.
